Panobinostat Lactate Patent Expiration
Panobinostat Lactate is Used for treating multiple myeloma in combination with bortezomib and dexamethasone. It was first introduced by Secura Bio Inc
Panobinostat Lactate Patents
Given below is the list of patents protecting Panobinostat Lactate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Farydak | US6552065 | Deacetylase inhibitors |
Aug 31, 2021
(Expired) | Secura |
| Farydak | US6833384 | Deacetylase inhibitors |
Sep 30, 2021
(Expired) | Secura |
| Farydak | US7067551 | Deacetylase inhibitors |
Aug 31, 2021
(Expired) | Secura |
| Farydak | US7989494 | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | Jan 17, 2028 | Secura |
| Farydak | US8883842 | Use of HDAC inhibitors for the treatment of myeloma | Jun 13, 2028 | Secura |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳